Hepatic complications of obesity.
Obesity is associated with a spectrum of chronic liver disease. Because obesity increases the risk for advanced forms of liver disease (ie, cirrhosis and liver cancer), the obesity epidemic is emerging as a major factor underlying the burden of liver disease in the United States and many other countries. This article reviews mechanisms that mediate the pathogenesis of obesity-related liver disease, summarizes clinical evidence that demonstrates obesity-related liver disease can be life-threatening, and discusses whether or not treatments for obesity or related comorbidities impact liver disease outcomes.
Diehl
Anna Mae
AM
Department of Medicine, Division of Gastroenterology, Duke University, Durham, NC 27710, USA. diehl004@mc.duke.edu
D050110:Bariatric Surgery; D001707:Biopsy, Needle; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D018450:Disease Progression; D005234:Fatty Liver / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000209:etiology; D008107:Liver Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology; D009765:Obesity / Q000150:complications* / Q000453:epidemiology; D009767:Obesity, Morbid / Q000453:epidemiology; D011379:Prognosis; D045162:Thiazolidinediones / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood; D015431:Weight Loss / Q000502:physiology
D045162:Thiazolidinediones; D000637:Transaminases